NCT06181838

Brief Summary

This study will compare the quality of life between 2 groups, which are group that receive standard moderate acne therapy in addition of lesion extractions, and the second group which only receive standard moderate acne therapy without lesion extractions.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
40

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Aug 2023

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

August 28, 2023

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 24, 2023

Completed
19 days until next milestone

First Submitted

Initial submission to the registry

December 13, 2023

Completed
13 days until next milestone

First Posted

Study publicly available on registry

December 26, 2023

Completed
8 days until next milestone

Study Completion

Last participant's last visit for all outcomes

January 3, 2024

Completed
Last Updated

December 29, 2023

Status Verified

December 1, 2023

Enrollment Period

3 months

First QC Date

December 13, 2023

Last Update Submit

December 24, 2023

Conditions

Outcome Measures

Primary Outcomes (1)

  • Quality of Life Score

    Measured using Acne-QoL-INA questionnaire

    Every 4 weeks, measured until 8 weeks

Secondary Outcomes (1)

  • Acne Grading

    Every 4 weeks, measured until 8 weeks

Study Arms (2)

Intervention

ACTIVE COMPARATOR

Standard therapy and lesion extraction

Procedure: Lesion extraction

Control

PLACEBO COMPARATOR

Standard therapy without lesion extraction

Drug: Tretinoin

Interventions

Tretinoin and benzoil peroxide used concurent in both groups as standard therapy

Also known as: Tretinoin, Benzoil peroxide
Intervention

Tretinoin and benzoil peroxide used concurent in both groups as standard therapy

Also known as: Benzoil peroxide
Control

Eligibility Criteria

Age18 Years - 59 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Clinically diagnosed as moderate acne vulgaris
  • Able to read and speak in Indonesia
  • Indonesian Citizen
  • Sign the consent form

You may not qualify if:

  • Pregnant of breastfeeding women
  • Acne vulgaris lesion located only outside of face
  • Experiencing COVID-19 symptoms
  • Using retinoid acid containing cream or benzoil peroxide in the last 2 weeks
  • Consume any oral antibiotics in the last 1 month
  • Injected with intralesional steroid or having acne lesions extracted in the last 2 weeks
  • Having laser or chemical peeling in the last 1 month

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Rumah Sakit Umum Pusat Nasional Dr. Cipto Mangunkusumo

Jakarta Pusat, DKI Jakarta, 10430, Indonesia

Location

MeSH Terms

Conditions

Acne Vulgaris

Interventions

Tretinoin

Condition Hierarchy (Ancestors)

Acneiform EruptionsSkin DiseasesSkin and Connective Tissue DiseasesSebaceous Gland Diseases

Intervention Hierarchy (Ancestors)

Vitamin ARetinoidsCarotenoidsPolyenesAlkenesHydrocarbons, AcyclicHydrocarbonsOrganic ChemicalsCyclohexenesCyclohexanesCycloparaffinsHydrocarbons, AlicyclicHydrocarbons, CyclicTerpenesDiterpenesPigments, BiologicalBiological Factors

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Medical Doctor

Study Record Dates

First Submitted

December 13, 2023

First Posted

December 26, 2023

Study Start

August 28, 2023

Primary Completion

November 24, 2023

Study Completion

January 3, 2024

Last Updated

December 29, 2023

Record last verified: 2023-12

Locations